Ghazal Nabil

Ms. Ghazal Nabil

Cairo University, Faculty of Veterinary Medicine, Department of Pharmacology
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GNGhazal Nabil
Ghazal Nabil
RARami M Alzhrani
Rami M Alzhrani
Hashem AlsaabHashem Alsaab
Hashem Alsaab
MAMohammed Atef
Mohammed Atef
SSSamaresh Sau
Samaresh Sau
HBHossny El Banna
Hossny El Banna
Identified as the second leading cause of cancer-related deaths among American women after lung cancer, breast cancer of all types has been the focus of numerous research studies. Even though triple-negative breast cancer (TNBC) represents 15–20% of the number of breast cancer cases worldwide, its existing therapeutic options are fairly limited. Due to the pivotal role of the presence/absence of specific receptors to luminal A, luminal B, HER-2+, and TNBC in the molecular classification of breast cancer, the lack of these receptors has accounted for the aforementioned limitation. Thereupon, in an attempt to participate in the ongoing research endeavors to overcome such a limitation, the conducted study adopts a combination strategy as a therapeutic paradigm for TNBC, which has proven notable results with respect to both: improving patient outcomes and survivability rates. The study hinges upon an investigation of a promising NPs platform for CD44 mediated theranostic that can be combined with JAK/STAT inhibitors for the treatment of TNBC. The ability of momelotinib (MMB), which is a JAK/STAT inhibitor, to sensitize the TNBC to apoptosis inducer (CFM-4.16) has been evaluated in MDA-MB-231 and MDA-MB-468. MMB + CFM-4.16 combination with a combination index (CI) ≤0.5, has been selected for in vitro and in vivo studies. MMB has been combined with CD44 directed polymeric nanoparticles (PNPs) loaded with CFM-4.16, namely CD44-T-PNPs, which selectively delivered the payload to CD44 overexpressing TNBC with a significant decrease in cell viability associated with a high dose reduction index (DRI). The mechanism underlying their synergism is based on the simultaneous downregulation of P-STAT3 and the up-regulation of CARP-1, which has induced ROS-dependent apoptosis leading to caspase 3/7 elevation, cell shrinkage, DNA damage, and suppressed migration. CD44-T-PNPs showed a remarkable cellular internalization, demonstrated by uptake of a Rhodamine B dye in vitro and S0456 (NIR dye) in vivo. S0456 was conjugated to PNPs to form CD44-T-PNPs/S0456 that simultaneously delivered CFM-4.16 and S0456 parenterally with selective tumor targeting, prolonged circulation, minimized off-target distribution.

11 January 2023 in Journal of Chemical Neuroanatomy
Verified
Journal Article
Closed access
SMSalma M. Mohamed
Salma M. Mohamed
MSMostafa A. Shalaby
Mostafa A. Shalaby
AAAsmaa K. Al‑Mokaddem
Asmaa K. Al‑Mokaddem
AEAhmed H. El-Banna
Ahmed H. El-Banna
HEHossny A. El-Banna
Hossny A. El-Banna
GNGhazal Nabil
Ghazal Nabil

29 February 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
GNGhazal Nabil
Ghazal Nabil
YAYasmine H. Ahmed
Yasmine H. Ahmed
OAOmaima Ahmed
Omaima Ahmed
SMSelvia S. Milad
Selvia S. Milad
MHMohamed Hisham
Mohamed Hisham
ASAya A. Shokry
Aya A. Shokry

23 February 2023 in Inflammopharmacology
Verified
Journal Article
Open access
PDF file
RERiham A. El-Shiekh
Riham A. El-Shiekh
GNGhazal Nabil
Ghazal Nabil
ASAya A. Shokry
Aya A. Shokry
YAYasmine H. Ahmed
Yasmine H. Ahmed
OAOthman S. S. Al-Hawshabi
Othman S. S. Al-Hawshabi
EAEssam Abdel-Sattar
Essam Abdel-Sattar
Acute lung injury (ALI) is a life-threatening condition usually associated with poor therapeutic outcomes and a high mortality rate. Since 2019, the situation has worsened due to the COVID-19 pandemic. ALI had approximately 40% of deaths before COVID-19, mainly due to the dysfunction of the blood–gas barrier that led to lung edema, failure of gas exchange, and dyspnea. Many strategies have been taken to mitigate the disease condition, such as diuretics, surfactants, antioxidants, glucocorticoids, heparin, and ventilators with concomitant sedatives. However, until now, there is no available effective therapy for ALI. Thus, we are presenting a new compound termed Arabincoside B (AR-B), recently isolated from Caralluma arabica, to be tested in such conditions. For that, the lipopolysaccharide (LPS) mice model was used to investigate the capability of the AR-B compound to control the ALI compared to standard dexamethasone. The results showed that AR-B had a significant effect on retrieving ALI. A further mechanistic study carried out in the serum, lung homogenate, histological, and immunohistochemistry sections revealed that the AR-B either in 50 mg/kg or 75 mg/kg dose inhibited pro-inflammatory cytokines such as IL-6, IL-13, NF-κB, TNFα, and NO and stimulated regulatory cytokines IL-10. Moreover, AR-B showed a considerable potential to protect the pulmonary tissue against oxidative stress by decreasing MDA and increasing catalase and Nrf2. Also, the AR-B exhibited an anti-apoptotic effect on the lung epithelium, confirmed by reducing COX and BAX expression and upregulating Bcl-2 expression. These results pave its clinical application for ALI.

23 April 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
ASAya A. Shokry
Aya A. Shokry
DBDina W. Bashir
Dina W. Bashir
NGNoha M. Gamil
Noha M. Gamil
GNGhazal Nabil
Ghazal Nabil

29 November 2021 in Journal of Herbmed Pharmacology
Verified
Journal Article
Open access
PDF file
MSMostafa Abass Shalaby
Mostafa Abass Shalaby
HBHossny El Banna
Hossny El Banna
SMSalma Mostafa Mohamed
Salma Mostafa Mohamed
GNGhazal Nabil
Ghazal Nabil
AEAhmed Hossny Elbanna
Ahmed Hossny Elbanna
Introduction: Echinacea purpurea is a flowering plant commonly used as an herbal medicine despite insufficient scientific bases to validate its usage. The present study aimed to examine in vitro and in vivo hepatoprotective effects of aqueous and alcoholic extracts of E. purpurea flowers. Methods: In vitro protection against hepato-cytotoxicity was carried out on human HepG-2 cells using colorimetric tetrazolium (MTT) assay, while the in vivo hepatoprotective activity was studied against carbon-tetrachloride (CCl4) induced acute hepatotoxicity in rats. Results: The results revealed that the extracts of E. purpurea induced discernable in vitro protection on HepG-2 cells and in vivo against CCl4 induced hepatotoxicity. Both extracts were significantly able to restore the serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, total protein, and albumin to normal levels compared to the CCl4 intoxicated group. In addition, the extracts markedly mitigated the oxidative stress by decreasing Malondialdehyde (MDA) and increasing superoxide dismutase (SOD) and glutathione (GSH) markers compared to the CCl4 intoxicated group. It was also associated with the down-regulation of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels in liver tissues. Histopathological examination revealed a decrease in hepatocytes’ degenerative changes and noticeable improvement of the liver damage by extracts of E. purpurea. Conclusion: These findings have proven that aqueous and alcoholic extracts of E. purpurea flowers have a significant hepatoprotective effect, probably owing to antioxidant, anti-inflammatory activities, and regulating apoptotic-related genes. This confirms the ethnomedicinal uses of E. purpurea in patients suffering from liver diseases.